Cancer Drug Discovery and Development

摘要: A significant amount of clinical research has been conducted with small molecules that inhibit matrix metalloproteinases (MMP), metal-containing enzymes degrade the extracellular and are implicated in tumor progression angiogenesis (1–3). The majority metalloproteinase inhibitors (MMPIs) designed a concept similar to protease used treatment acquired immunodeficiency syndrome. MMPIs currently under development for variety diseases most notably cancer (3). Unlike conventional chemotherapy or radiation therapy, expected slow growth prolong survival without causing detectable shrinkage tumors. Because predicted but not shrink tumors, is guided purely by objective responses; proving therapeutic value these will therefore require randomized placebo-controlled trials assessment impact drug compared placebo. Proof compounds effective cytostatic agents demonstrating advantage when placebo randomized, controlled trial.